{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-002883","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2026-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.651895+00:00","generated_at":"2026-05-16T09:36:46.056790+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MAIA Biotechnology updates ateganosine program, targeting early commercial approval in NSCLC","bullets":["Ateganosine obtained FDA Fast Track designation for NSCLC in 2025; company expects potential Accelerated Approval and Priority Review.","Initiated THIO-104 Phase 3 trial in 3L NSCLC; Phase 2 Part C expansion underway in Asia and Europe.","Awarded $2.3M NIH grant for Phase 2 trial; raised ~$17.6M in 2025 capital raises with board participation.","Targeted 2026 milestones: interim efficacy data from Phase 3, completion of Phase 2 Part C, and start of Phase 1 for second-generation molecules.","Company claims ateganosine is the only telomere-targeting anticancer agent in clinical development globally."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-002883","json":"https://secwatch.observer/filing/0001493152-26-002883.json","markdown":"https://secwatch.observer/filing/0001493152-26-002883.md","text":"https://secwatch.observer/filing/0001493152-26-002883.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000149315226002883/0001493152-26-002883-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000149315226002883/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:36:46.056790+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}